Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Sunshine Biopharma ( (SBFM) ) has issued an update.
Sunshine Biopharma reported a significant revenue increase of 78% in 2022, reaching $5.2 million. The company completed a public offering to expand sales operations and launched 14 new generic drugs. It received regulatory approval from Health Canada for its oncology drug, NIPEGS™, and published groundbreaking research on its coronavirus PLpro inhibitor. Additionally, the company completed mouse model studies for its mRNA Lipid Nanoparticle as a novel therapeutic agent for liver cancer, marking important milestones in its drug development program.
More about Sunshine Biopharma
Sunshine Biopharma Inc. is a pharmaceutical company engaged in offering and researching life-saving medicines across various therapeutic areas, including oncology and antivirals. The company currently markets 23 generic prescription drugs in Canada and plans to launch 16 additional drugs in 2023, including a biosimilar of NEULASTA®.
YTD Price Performance: -33.55%
Average Trading Volume: 86,191
Technical Sentiment Signal: Strong Buy
Current Market Cap: $5.17M
Find detailed analytics on SBFM stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue